Decitabine
Dacogen
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Accepting patients
A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Learn more- BCL-2 Inhibitor
- Phase 1/2
Accepting patients
A Phase I/II Study of Venetoclax in Combination With ASTX727 (Cedazuridine/Decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1/2
- Has results
Accepting patients
Pembrolizumab, Decitabine +/- Venetoclax
Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Monoclonal Antibody
- Phase 1
Accepting patients
Azacitidine and Decitabine
Proof-Of-Concept Study of Metabolically Optimized, Non-Cytotoxic 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Learn more- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
Cytarabine Alternating with Decitabine
Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Learn more- Hypomethylating Agents (HMA)
- Phase 2
Accepting patients
Quizartinib with Decitabine and Venetoclax
A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
Gemtuzumab as Part of Chemotherapy
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
Learn more- Antibody Drug Conjugate (ADC)
- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- CD33
- Phase 2
Accepting patients
TWT-202
Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML
Learn more- Hypomethylating Agents (HMA)
- PLK4 Inhibitor
- Phase 1/2
- Has results
Accepting patients
MORE
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Learn more- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- Maintenance
- Phase 2
Accepting patients
Decitabine Plus a JAK-Inhibitor
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
Learn more- Hypomethylating Agents (HMA)
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 2